When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Mechanism of Action
Evista is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors. Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.
- Allergic reaction to the active substance or to any of the excipients of the drug.
- Must not be used in women with child bearing potential .
- Active or past history of venous thromboembolic events (VTE), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.
- Hepatic impairment including cholestasis.
- Severe renal impairment.
- Unexplained uterine bleeding.
- Evista should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Adverse events associated with the use of Evista may include, but are not limited to, the following:
- Hot Flashes
- Body Infection
- Flu Syndrome
Store at room temperature. Protect from heat, light and moisture. Keep away from reach of children.
For other health product please visit : Zithromax, Proscar,buy protonix online, zyban, Nizoral etc.